

29 August 2025

Appendix 4E - Results for Announcement to the Market

Provided below are the Results for Announcement to the Market in accordance with ASX Listing Rule 4.3A and Appendix 4E for EVE Health Group and its controlled entities for the financial year ended 30 June 2025 (the reporting period) compared with the financial year ended 30 June 2024 (the prior period).

				\$
Revenue from ordinary activities	Down	19%	to	1,734,726
Loss after tax from continuing operations attributable to members	Down	6%	to	(1,452,957)
Loss after tax from discontinued operations attributable to members	Down	64%	to	(126,998)
Net loss for the period attributable to members	Down	17%	to	(1,579,955)

Net tangible assets per security

The net tangible assets per ordinary security is \$0.0023 (2024: \$0.0093).

Dividends

No dividends were paid, declared or determined during the reporting period.

Details of associates and joint venture entities

N/A

Details of entities over which control was gained or lost during the period

Independent auditor's report

The Consolidated Financial Statements upon which this Appendix 4E is based have been audited and the Independent Auditor's Report to the shareholders of EVE Health Group Limited is included in the 2025 Annual Report that accompanies this announcement.

Commentary

Commentary on the results for the reporting period is contained within the 2025 Annual Report.

Authorised for release by the Board of Directors.

For more information, please contact: Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

